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ABSTRACT 
Lipids have many central physiological roles including as structural components of cell 
membranes, energy storage sources and intermediates in signaling pathways. Lipid-related 
disturbances are known to underlie many diseases and their co-morbidities. The emergence of 
lipidomics has empowered researchers to study lipid metabolism at the cellular as well as 
physiological levels at a greater depth than was previously possible. The key challenges ahead 
in the field of lipidomics in medical research lie in the development of experimental protocols 
and in silico techniques needed to study lipidomes at the systems level. Clinical questions where 
lipidomics may have an impact in healthcare settings also need to be identified, both from the 
health outcomes and health economics perspectives. 
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Highlights 
 Lipidomics is a key platform for the study of lipid metabolism in health and disease. 
 Multiple suitable techniques for the global measurement of molecular lipids exist. 
 New experimental protocols are needed to study lipidomes at physiological level.  
 Better in silico tools are needed to study lipids at the systems level. 
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1. INTRODUCTION 
Over the past decade, lipidomics emerged as a key approach aimed at elucidating lipid-related 
pathways and mechanisms underlying the cellular function. Additionally, due to the 
undeniable role of lipids in the maintenance of system homeostasis at the cellular as well as 
physiological levels, lipidomics also emerged as a powerful tool for identifying the key 
processes and related molecular signatures associated with progression to and protection from 
many diseases [1, 2]. Biological importance of lipids is not only due to their roles in biochemical 
and signaling pathways, but also due to them being part of lipid-containing ensembles such as 
cell membranes and lipid particles (e.g., lipoproteins and exosomes). In order to understand the 
roles of lipids in specific pathologies, it is therefore essential to adopt a systems approach which 
accounts for spatial and dynamic complexity of lipid metabolism [3]. 
 
Much of the debate concerning lipidomics applications in health and disease has been about the 
advantages or disadvantages of specific technologies for the measurement of lipids. However, 
the current methods such as based on shotgun mass spectrometry (MS) and liquid 
chromatography (LC)-MS, each with its own advantages and disadvantages, are all applicable 
for the studies of biological systems including in clinical settings, as long as they are properly 
optimized and their pro-s and con-s are understood.  
 
Here we focus on selected practical considerations when choosing and developing lipidomics 
methods as well as highlight key considerations and challenges. 
 
2. SAMPLE PREPARATION FOR LIPIDOMIC ANALYSIS 
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Regardless of the analytical method used for lipidomics data acquisition, lipids need to be 
extracted from the biological samples. Sample preparation has a major impact both on the 
quality as well as on the sample throughput in lipidomics [4]. Different types of sample 
matrices may also require different types of sample preparation protocols.  
 
There are several studies comparing different sample preparation methods, yet the results 
have not always been consistent [5-8]. Criteria for the selection of the most suitable sample 
preparation protocol should include assessment of the lipid coverage and recovery, simplicity 
of the procedure, protein removal efficiency, repeatability of lipids measurements, costs and 
feasibility for automation. Among the most commonly used lipid extraction methods, the 
protocols based on chloroform:methanol (CHCl3:MeOH) [9, 10] can be problematic with 
robotic pipetting systems, as the extract is in the lower phase, and the collection of the extract 
through the aqueous phase and through the protein layer may cause contamination and 
clogging. The methyl-tert-butyl ether (MTBE):MeOH protocol [11], on the other hand, has a 
high sample-to-solvent ratio, making it more challenging to use with 96-well plates [5].  
 
Sensitivity of MS instruments has improved considerably over the past years, to the point that 
this is no longer a major issue as compared to the issues related to sampling and sample 
preparation. Much of the analytical variation and loss of lipids occurs at these initial stages of 
lipidomic analysis, which is particularly true when studying lipid mediators and oxidized 
lipids. When analyzing the human samples (biopsies, blood), where time of sample exposure 
at room temperature after the sampling often cannot be fully controlled for, there is a risk that 
the measured concentrations of lipids may not truly reflect their actual endogenous levels but 
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are instead the artifacts of sampling. More systematic studies are needed that address the 
effect of sampling (and sample types) on lipid concentrations [12], and ultimately consensus 
should be sought about the optimal sampling procedures for specific sample types and lipid 
classes. 
 
3. QUANTIFICATION OF LIPIDS – DIFFERENT APPROACHES TO LIPIDOMICS  
The term ‘quantitative analysis’ is often used rather loosely in life sciences. Terms such as 
‘quantitation’ and ‘absolute quantitation’ have been applied in the fields of proteomics and 
lipidomics, even though the analyses applied were strictly speaking semi-quantitative. For an 
analytical chemist, quantitative analysis means that each compound analyzed is quantified 
against a structurally equivalent compound which is used as an internal standard (i.e., isotope 
labeled standards each corresponding to each of the individual molecules measured), and 
calibration curves for each separate compound over the entire concentration range measured. 
For quantitative analysis, FDA guidelines state that calibration curve should be generated for 
each analyte in the sample [13]. Therefore, the global lipidomic analyses do not fulfill the criteria 
of being fully quantitative analysis (neither the LC-MS nor the shotgun based methods).   
 
In the field of metabolomics, it is still a common practice to use normalization procedures which 
are not based on internal standards, e.g., by using the sum of total signal. This approach is, 
however, not recommended for lipidomics and it is also problematic for metabolomics 
applications in general. As discussed in detail earlier [14], the total amount of lipids in tissues 
and biofluids may vary considerably across different study groups. Normalization based on 
data-derived measures such as total signal may thus inevitably skew the results.  
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The use of lipid-class-specific standards for normalization and quantitation is not fully accurate 
either, because different lipids typically have quantitatively different MS responses. For 
example, for phospholipids, the MS response for both saturated and unsaturated lipids 
decreases with increasing acyl-chain length. In addition, the differences in overall lipid 
concentrations in the study samples further enhance this phenomenon. With increasing number 
of standard compounds for the analysis of lipids being commercially available, the accuracy of 
quantification is bound to improve considerably in the future, although strictly speaking the 
global lipidomics approaches are likely to remain semi-quantitative. Systematic studies are 
needed which will examine the effect of sample matrix, e.g., across a wide range of physiological 
conditions of interest, on measured lipid levels. 
 
Both the shotgun lipidomics and LC-MS approach have their own advantages and 
disadvantages [4, 15]. In the shotgun approach, the main advantage is that the sample is infused 
to the MS at a constant concentration and thus, the inevitable matrix effect (mainly ion 
suppression) is relatively constant, and internal standard normalization may work well if the 
lipid profiles between the study groups do not vary too considerably. In LC-MS, lipids are 
separated prior to the introduction to MS, thus reducing the matrix effects and improving the 
sensitivity, however, because the internal standards do not elute at the same time as most of the 
lipids, the normalization may work very well for part of the compounds and less so for the 
others. This is, however, a slightly simplistic view of the matrix effects. In shotgun MS, the total 
lipid concentration affects the ionization process. At high(er) concentrations, lipids can 
aggregate, and the aggregates cannot be efficiently ionized or reliably detected. Thus, in the 
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aggregation state, the ionization efficiency becomes dependent on the lipid species (the acyl-
chain length, number of double bonds). The lipid concentration at which aggregation occurs 
depends on the solvent. For example, in CHCl3:MeOH, which is typically used for lipid 
extraction, the critical lipid concentration varies with the proportion of methanol, from ca. 10 
pmol mL-1 (CHCl3:MeOH, 1:2) to 200 pmol mL-1 in (CHCl3:MeOH, 2:1). The challenge of finding 
the optimal concentration is that the total lipid concentrations in biological samples can vary 
considerably. For example, the total lipid concentration in human plasma is ca. 8000 nmol mL-
1. However, some lipid concentrations can be clearly higher, e.g., in subgroups of obese 
individuals where the plasma triacylglycerols are elevated. Dilution of the samples is therefore 
typically needed in shotgun approaches. However, it is not always possible to determine the 
correct degree of dilution before the experiments.  
 
4. QUALITY CONTROL  
Strict quality control (QC) in lipidomics is crucial, particularly when a large number of samples 
are analyzed. In lipidomics, repeatability is one of the most important criteria to assure the 
reliability of the various analytical assays. It is essential that internal standards are used for 
normalization, the samples are prepared and analyzed in random order, and sufficient amount 
of different types of quality control samples and blanks are analyzed together with the samples 
(Table 1).  
 
Large-scale lipidomic analyses are typically performed in batches, and even under repeatable 
conditions, instrumental variation in MS techniques applied might arise for a number of 
reasons. These include for example drifts in sensitivity, ionization efficiency, and gradual 
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changes in column performance (in LC-MS) over the analysis periods. Batch effects can be 
corrected for by using different methodologies [16], and there is still no consensus which is the 
best method for batch effect correction. In our research, we consider that batch correction should 
be applied with caution. If no deviations from the accepted QC cut-off values (RSD in control 
samples) occur, the batch correction may not be needed. If there are some deviations and there 
is a clear batch pattern over the course of the analysis, correction may be however merited. The 
choice of the correction ultimately depends on the nature of the batch effect.  
 
5. LIPIDOMICS DATA PROCESSING AND ANALYSIS 
Data processing is a crucial step, which transforms raw lipidomics data into an interpretable 
dataset amenable to statistical and pathway analysis. Several tools are available for lipidomics 
data processing, both for shotgun and LC-MS approaches [17, 18]. In addition to the solutions 
developed by the research community, the MS instrument vendors have also started to offer 
increasingly sophisticated solutions for processing and analysis of lipidomics data. The choice 
of the data processing solution may depend on many factors, including local set-up of the 
lipidomics platform, software expertise and ambition as well as familiarity with a specific 
methodology. It is essential that any data processing solution is thoroughly evaluated and tested 
as part of lipidomics method development and validation, before putting it to use. Open-source 
packages such as XCMS [19, 20] and MZmine [21, 22] may be initially more demanding for non-
expert users, yet they may offer more flexibility as compared to alternative ‘black box’ software 
solutions. 
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Similarly as in metabolomics and other ‘omics’ approaches, high dimensionality of lipidomics 
data needs to be taken into account when analyzing them [17, 23]. When analyzing the data at 
the individual lipid level, rate of type I errors in null hypothesis testing needs to be taken into 
account when conducting multiple comparisons, such as by controlling for False Discovery rate 
[24]. However, lipids commonly exert their function as ensembles. The bioinformatics challenge 
is therefore how to best account for such a high degree of co-regulation [3, 25]. 
 
6. LIPID IDENTIFICATION 
In most cases, the identification of lipids is generally not as challenging as e.g. for the polar 
metabolites, because lipids comprise common structural blocks that can be detected by MS/MS 
(or more broadly MSn) analysis. This makes lipid identification also amenable to automated 
computational approaches [26]. Current high-resolution MS instruments in most cases afford 
reliable identification of major lipids (apart from double bond and acyl chain position).  
 
Much of the ambiguity concerning the reported lipid identities and their amounts comes from 
the differences in lipid annotation, and there is a clear need for consensus. The proposed 
shorthand nomenclature by Liebisch et al. provides an excellent starting point for this purpose 
[27]. The ambiguity in lipid annotation may also affect the reported lipid concentrations. For 
example, in LC-MS lipidomics, multiple lipid species may be reported containing the same 
carbon number and double bond count, based on their chromatographic separation. While some 
may prefer to determine the total amount of lipid corresponding to a specific carbon number 
and double bond count, alternatively one may also treat each individual lipid (corresponding 
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to a specific retention time) separately. The reported concentration of lipids in such ambiguous 
cases may therefore be considerably different, depending on the approach taken.  
 
7. MODELING OF LIPID METABOLISM 
Elucidation of lipid metabolism and its complex dynamics at physiological or cellular levels can 
only be achieved in dedicated experimental settings which are not feasible in most clinical 
lipidomics studies. Nevertheless, functional studies even if limited in sample size, such as by 
using stable isotope tracers or focusing on lipidomic profiling in isolated lipoprotein fractions 
[28-30], are highly important if one is to interpret lipidomic profiles in the physiological context.  
 
One important emerging tool for modelling metabolic networks including lipid metabolism is 
the constraint-based modeling (CBM) approach. CBM relies on simpler physical-chemical 
constraints and has shown a remarkable predictive signal in the analysis of metabolic systems 
on a genome scale [31, 32]. Genome-scale reconstruction collects all of the relevant metabolic 
information of an organism and compiles it in a mathematical model, which connects genes 
(e.g., those expressing specific enzymes) with metabolic pathways. Constraining the genome 
scale network reconstruction provides the allowable network space, i.e., the space of feasible 
flux distributions. While genome-scale CBM is increasingly being used as an integrative 
modeling tool in metabolomics including in clinical setting [33], the approach has not yet been 
widely adopted in lipidomics. This is mainly because the current genome scale metabolic 
reconstructions still poorly annotate lipid metabolism at the molecular level – although progress 
has been made [34]. Advances in functional lipidomics and metabolic reconstructions are likely 
to lead to much improved metabolic models in the future. 
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8. IMPACT OF LIPIDOMICS IN CLINICAL RESEARCH 
In clinical research, the main challenge is not in the technologies applied, but rather in 
identifying the problems where the identification of lipid-related markers may have an impact. 
Since lipid homeostasis is fundamental to maintain health, specific lipid disturbances may be 
an underlying link and shared across multiple co-morbid conditions behind specific diseases. 
Lipidomics may therefore be a valuable tool for identifying particularly vulnerable co-morbid 
sub-populations which would benefit from a specific therapy. For example, we have recently 
shown that those first episode psychotic patients who are at the highest risk of rapid weight 
gain are characterized by a specific lipidomic profile at baseline [35], similar to the one observed 
earlier in patients with non-alcoholic fatty liver disease (NAFLD) [36] and in those at risk of 
developing T2D [37]. Those patients may therefore benefit from a combined antipsychotic and 
anti-obesity treatment, a therapeutic strategy that has already been considered due to the 
significant public health burden of metabolic co-morbidities that are associated with the 
psychotic disorders [38].  
 
When considering clinical applications of lipidomics, the obvious question is also if and where 
lipidomics can have a public health impact? While undoubtedly lipidomics research has already 
provided valuable and novel pathophysiological insights as well as biomarker candidates in 
many diseases, and thus also opened novel therapeutic avenues, translation of such research 
outcomes into applications in healthcare settings is an entirely different challenge. Particularly 
in diseases affecting large fraction of the population such as in type 2 diabetes (T2D), health 
economics is also an important consideration in addition to the health outcomes. Since lifestyle 
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plays a major role in acquiring risk of T2D, much of the relevant data for risk assessment may 
be easily obtained by existing routine clinical tests and by real-time monitoring of lifestyle (e.g., 
diet, exercise, sleep via mobile phone applications). If lipidomics is to deliver in this domain, the 
lipidomic test has to be inexpensive and its added value needs to be demonstrated in a 
prospective setting with respect to health economics and outcomes. The ‘regulatory paths’ also 
need to be identified in a disease-specific manner, which would clarify the steps needed to 
translate research findings into the applications in the clinic – which may also require 
developments of cost effective and quantitative assays for the analysis of specific lipids.  
 
9. CONCLUDING REMARKS 
Lipidomics led to many advances in the studies of health and disease over the past decade, 
providing valuable insights into the mechanisms and molecular signatures behind specific 
diseases and their co-morbidities. The field has matured to the point that the introduction of 
lipidomics into clinical practice is being considered and debated. While much of the discussion 
has so far focused on specific technologies for the measurement of lipids at the molecular level, 
the key challenges ahead lie elsewhere. These non-exclusively include identification of clinical 
questions where lipidomics may have an impact in healthcare settings as well as development 
of experimental protocols and in silico techniques needed to study lipidomes at the systems 
level. 
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Table 1. Quality control and standard samples for lipidomics. 
 
Sample Type Use Frequency 
Quality control 
sample 
Pooled sample with 
an aliquot of each 
sample or surrogate 
sample with similar 
lipid composition 
than the samples 
For quality 
monitoring, correction 
of possible batch 
effects 
After every 6-12 
study samples* 
Certified reference 
material 
SRM 1950 - 
Metabolites in Frozen 
Human Plasma** 
Allows comparison of 
results in different 
studies 
Triplicate in each 
batch 
Blank sample Blank sample treated 
in the same way as all 
the samples 
Shows the possible 
contaminants from 
sample preparation 
and analysis 
After every 6-12 
samples 
Pure standards Standards in solvent, 
including ISTDs 
Shows the 
performance of the 
instrument 
After every 6-12 
samples 
Calibration samples Six different 
concentrations of 
standards, with 
internal standards 
For (semi)quantitation In the beginning, 
middle and end 
of a batch in large 
series 
 
*The minimum number of QC samples to ensure proper control of the assay should be at least 5 % 
of the number of unknown samples or a total of six QC samples, whichever is greater (FDA). 
**Quantitative levels of over 500 different lipid molecular species have been reported [39]. 
 
